Full Text Journal Articles by
Author Yuki Tahata

Advertisement

Find full text journal articles








Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals.

Yuki Tahata, Ryotaro Sakamori, Ryoko Yamada, Takahiro Kodama, Hayato Hikita, Hideki Hagiwara, Yasuharu Imai, Naoki Hiramatsu, Shinji Tamura, Keiji Yamamoto, Masahide Oshita, Kazuyoshi Ohkawa, Taizo Hijioka, Hiroyuki Fukui, Toshifumi Ito, Yoshinori Doi, Yukinori Yamada, Takayuki Yakushijin, Yuichi Yoshida, Tomohide Tatsumi, Tetsuo Takehara, ,

<h4>Background</h4>Several factors associated with hepatocellular carcinoma (HCC) occurrence after sustained virological response (SVR) in patients with hepatitis C have been reported. However, few validation studies have been performed in the era of direct-acting anti-virals (DAAs).<h4>Aims</h4>To develop a prediction model for HCC occurrence after DAA-mediated SVR and validate its usefulness.<h4>Methods</h4>We analysed ... Read more >>

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, :]

Cited: 0 times

View full text PDF listing >>



White Adipose Tissue Autophagy and Adipose-Liver Crosstalk Exacerbate Nonalcoholic Fatty Liver Disease in Mice.

Sadatsugu Sakane, Hayato Hikita, Kumiko Shirai, Yuta Myojin, Youichi Sasaki, Shinnosuke Kudo, Kenji Fukumoto, Naoki Mizutani, Yuki Tahata, Yuki Makino, Ryoko Yamada, Takahiro Kodama, Ryotaro Sakamori, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Background & aims</h4>Although nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity, the role of adipose tissue in NAFLD is not well-understood. Because autophagy has been reported to be involved in the degradation of lipid droplets, we investigated the role of adipose tissue autophagy in the liver pathogenesis of ... Read more >>

Cell Mol Gastroenterol Hepatol (Cellular and molecular gastroenterology and hepatology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.

Kazuhiro Kozumi, Takahiro Kodama, Hiroki Murai, Sadatsugu Sakane, Olivier Govaere, Simon Cockell, Daisuke Motooka, Naruyasu Kakita, Yukinori Yamada, Yasuteru Kondo, Yuki Tahata, Ryoko Yamada, Hayato Hikita, Ryotaro Sakamori, Yoshihiro Kamada, Ann K Daly, Quentin M Anstee, Tomohide Tatsumi, Eiichi Morii, Tetsuo Takehara,

<h4>Background and aims</h4>NAFLD is the most common liver disease worldwide. NASH, the progressive form of NAFLD, and advanced fibrosis are associated with poor outcomes. We searched for their noninvasive biomarkers.<h4>Approach and results</h4>Global RNA sequencing of liver tissue from 98 patients with biopsy-proven NAFLD was performed. Unsupervised hierarchical clustering well distinguished ... Read more >>

Hepatology (Hepatology (Baltimore, Md.))
[2021, :]

Cited: 1 time

View full text PDF listing >>



Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment.

Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Yuki Tahata, Masahide Oshita, Hideki Hagiwara, Mitsuru Sakakibara, Shinji Tamura, Naoki Hiramatsu, Masami Inada, Sadaharu Iio, Toshifumi Ito, Takayuki Yakushijin, Yoshinori Doi, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Aim</h4>The aim of the present study was to investigate the clinical course in hepatitis C virus (HCV)-positive patients with decompensated liver cirrhosis after direct-acting antivirals (DAAs) have been used for HCV infection.<h4>Methods</h4>This multicenter study prospectively analyzed a registered cohort composed of 73 HCV-positive patients with decompensated cirrhosis who attended our ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2021, 51(5):517-527]

Cited: 0 times

View full text PDF listing >>



Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis.

Ryotaro Sakamori, Ryoko Yamada, Kazuma Shinkai, Akira Doi, Yuki Tahata, Minoru Shigekawa, Takahiro Kodama, Hayato Hikita, Tomomi Yamada, Tomohide Tatsumi, Tetsuo Takehara,

Hepatitis C virus (HCV) can be eliminated by direct-acting antivirals in patients with decompensated liver cirrhosis. Although viral clearance in decompensated liver cirrhosis leads to improvement of the liver function and quality of life, changes in the skeletal muscle mass after sustained virologic response (SVR) in patients with decompensated liver ... Read more >>

Intern Med (Internal medicine (Tokyo, Japan))
[2021, 60(5):745-750]

Cited: 1 time

View full text PDF listing >>



Efficacy of Ramucirumab Versus Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma.

Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Yuki Tahata, Kazuyoshi Ohkawa, Masahide Oshita, Shinji Tamura, Hideki Hagiwara, Eiji Mita, Takayuki Yakushijin, Masami Inada, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Background/aim</h4>The present study aimed to examine the therapeutic efficacy of ramucirumab compared with that of sorafenib as subsequent systemic therapy for patients with hepatocellular carcinoma (HCC) and serum α-fetoprotein (AFP) levels ≥400 ng/ml.<h4>Patients and methods</h4>In our prospectively registered, real-world cohort, 13 and 11 patients treated with ramucirumab or sorafenib, respectively, ... Read more >>

Anticancer Res (Anticancer research)
[2021, 41(4):2187-2192]

Cited: 0 times

View full text PDF listing >>



Initial treatment response to transarterial chemoembolization as a predictive factor for Child-Pugh class deterioration prior to refractoriness in hepatocellular carcinoma.

Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Yuki Tahata, Yasuharu Imai, Masahide Oshita, Kazuyoshi Ohkawa, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

AIM:Repeated transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (HCC) eventually leads to either deteriorated hepatic reserve or TACE refractoriness. Switching to molecular targeted agents after TACE requires preservation of hepatic reserve. This study aimed to investigate the predictive factors associated with early deterioration of hepatic reserve by repeated TACE prior ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2020, 50(11):1275-1283]

Cited: 0 times

View full text PDF listing >>



Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.

Yuki Tahata, Hayato Hikita, Satoshi Mochida, Norifumi Kawada, Nobuyuki Enomoto, Akio Ido, Hitoshi Yoshiji, Daiki Miki, Yoichi Hiasa, Yasuhiro Takikawa, Ryotaro Sakamori, Masayuki Kurosaki, Hiroshi Yatsuhashi, Ryosuke Tateishi, Yoshiyuki Ueno, Yoshito Itoh, Taro Yamashita, Tatsuya Kanto, Goki Suda, Yasunari Nakamoto, Naoya Kato, Yasuhiro Asahina, Kentaro Matsuura, Shuji Terai, Kazuhiko Nakao, Masahito Shimizu, Taro Takami, Norio Akuta, Ryoko Yamada, Takahiro Kodama, Tomohide Tatsumi, Tomomi Yamada, Tetsuo Takehara,

<h4>Background</h4>Real-world data on the efficacy and safety of sofosbuvir plus velpatasvir (SOF/VEL) treatment for patients with hepatitis C virus (HCV)-related decompensated cirrhosis are limited in Japan.<h4>Methods</h4>A total of 190 patients with compensated (108) or decompensated (82) cirrhosis who initiated direct-acting antiviral (DAA) treatment between February 2019 and August 2019 were ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2021, 56(1):67-77]

Cited: 2 times

View full text PDF listing >>



Clinical outcomes of direct-acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment.

Yuki Tahata, Ryotaro Sakamori, Ayako Urabe, Ryoko Yamada, Kazuyoshi Ohkawa, Naoki Hiramatsu, Hideki Hagiwara, Masahide Oshita, Yasuharu Imai, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Aim</h4>It remains unclear how direct-acting antiviral (DAA) treatments influence hepatocellular carcinoma (HCC) recurrence and survival in comparison with interferon (IFN).<h4>Methods</h4>In total, 338 patients with chronic hepatitis C virus (HCV) infection and previous HCC treatments who initiated IFN (N = 88, IFN group) or DAA treatment (N = 250, DAA group) from January 2005 to ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2020, 50(10):1118-1127]

Cited: 1 time

View full text PDF listing >>



Therapeutic efficacy of lenvatinib in hepatocellular carcinoma patients with portal hypertension.

Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Ayako Urabe, Yuki Tahata, Masahide Oshita, Kazuyoshi Ohkawa, Eiji Mita, Hideki Hagiwara, Shinji Tamura, Toshifumi Ito, Takayuki Yakushijin, Sadaharu Iio, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Aim</h4>Preserved liver function may be an important factor affecting therapeutic efficacy in hepatocellular carcinoma patients treated with lenvatinib, but not all patients can be treated while preserving liver function. This study evaluated the therapeutic efficacy of lenvatinib in patients with poor liver function with and without portal hypertension.<h4>Methods</h4>This prospectively registered ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2020, 50(9):1091-1100]

Cited: 0 times

View full text PDF listing >>



Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.

Naoki Morishita, Ryotaro Sakamori, Tomomi Yamada, Yugo Kai, Yuki Tahata, Ayako Urabe, Ryoko Yamada, Takahiro Kodama, Hayato Hikita, Yoshinori Doi, Shinji Tamura, Hideki Hagiwara, Yasuharu Imai, Sadaharu Iio, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Background</h4>L31 and Y93 in the NS5A region of the hepatitis C virus (HCV) are the most important substitution positions associated with resistance to direct-acting antiviral (DAA) treatment.<h4>Methods</h4>We analyzed the frequency of NS5A L31M/V and Y93/H in NS5A inhibitor-naive HCV genotype 1 patients who received asunaprevir plus daclatasvir combination treatment using ... Read more >>

PLoS One (PloS one)
[2020, 15(6):e0234811]

Cited: 0 times

View full text PDF listing >>



Lower Serum Sodium Levels Are Associated with the Therapeutic Effect of Sorafenib on Hepatocellular Carcinoma.

Tadashi Kegasawa, Ryotaro Sakamori, Kazuki Maesaka, Ryoko Yamada, Yuki Tahata, Ayako Urabe, Takahiro Kodama, Hayato Hikita, Kazuho Imanaka, Kazuyoshi Ohkawa, Naoki Hiramatsu, Masahide Oshita, Yukinori Yamada, Masami Inada, Takayuki Yakushijin, Yasuharu Imai, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Background and aim</h4>Although the serum sodium level has been reported to be a prognostic and predictive marker for the therapeutic effects of lung cancer and renal cell carcinoma treated with molecular targeted therapy, the serum sodium level has not been investigated in hepatocellular carcinoma (HCC) patients treated with sorafenib. The ... Read more >>

Dig Dis Sci (Digestive diseases and sciences)
[2021, 66(5):1720-1729]

Cited: 0 times

View full text PDF listing >>



Hepatocellular carcinoma occurrence does not differ between interferon-based and interferon-free treatment with liver histological assessment.

Yuki Tahata, Ryotaro Sakamori, Ayako Urabe, Ryoko Yamada, Kazuyoshi Ohkawa, Naoki Hiramatsu, Hideki Hagiwara, Masahide Oshita, Taizo Hijioka, Shinji Tamura, Yasuharu Imai, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Aim</h4>Several studies have recently reported that hepatocellular carcinoma (HCC) occurrence does not differ between hepatitis C virus patients receiving interferon (IFN)-based and IFN-free treatments considering the patients' backgrounds. However, liver fibrosis was not directly considered in these studies.<h4>Methods</h4>In total, 3972 patients without a history of HCC who started IFN-based or IFN-free ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2020, 50(3):313-320]

Cited: 0 times

View full text PDF listing >>



Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma.

Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Yuki Tahata, Ayako Urabe, Minoru Shigekawa, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

AIM:Intermediate-stage hepatocellular carcinoma (HCC) targeted for transcatheter arterial chemoembolization (TACE) corresponds to a highly heterogeneous population for whom the factors predicting TACE efficacy have not been established. This study aimed to evaluate the impact of hypovascular hepatic nodules coexisting with intermediate-stage HCC as a significant predictive factor for TACE refractoriness. ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2020, 50(3):365-373]

Cited: 3 times

View full text PDF listing >>



Cotreatment with lenvatinib and warfarin potassium caused prothrombin time prolongation.

Yoichi Sasaki, Ryotaro Sakamori, Ryoko Yamada, Minoru Shigekawa, Yuki Tahata, Yuki Makino, Tasuku Nakabori, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

Lenvatinib is approved as a standard systemic therapy for unresectable hepatocellular carcinoma (HCC) patients; however, experience with lenvatinib in clinical practice is insufficient. We present the case of a patient with advanced HCC whose prothrombin time - international normalized ratio (PT-INR) was elevated after cotreatment with lenvatinib and warfarin potassium. ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2019, 49(11):1357-1361]

Cited: 0 times

View full text PDF listing >>



Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response.

Ryoko Yamada, Naoki Hiramatsu, Tsugiko Oze, Ayako Urabe, Yuki Tahata, Naoki Morishita, Takahiro Kodama, Hayato Hikita, Ryotaro Sakamori, Takayuki Yakushijin, Akira Yamada, Hideki Hagiwara, Eiji Mita, Masahide Oshita, Toshifumi Itoh, Hiroyuki Fukui, Yoshiaki Inui, Taizo Hijioka, Masami Inada, Kazuhiro Katayama, Shinji Tamura, Atsuo Inoue, Yasuharu Imai, Tomohide Tatsumi, Toshimitsu Hamasaki, Norio Hayashi, Tetsuo Takehara,

<h4>Aim</h4>In patients with chronic hepatitis C, hepatocellular carcinoma (HCC) occurs at a certain frequency, even if a sustained virologic response (SVR) is achieved by antiviral treatment. Old age, liver fibrosis, and high post-treatment α-fetoprotein (AFP) level are typical risk factors of post-SVR HCC. We examined whether the frequencies and factors ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2019, 49(5):570-578]

Cited: 7 times

View full text PDF listing >>



Predictive factors of anemia during sofosbuvir and ribavirin therapy for genotype 2 chronic hepatitis C patients.

Ayako Urabe, Ryotaro Sakamori, Yuki Tahata, Ryoko Yamada, Yasuharu Imai, Hideki Hagiwara, Shinji Tamura, Hiroyuki Fukui, Yukinori Yamada, Akira Kaneko, Taizo Hijioka, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Aim</h4>Sofosbuvir (SOF) and ribavirin (RBV) combination therapy has improved the sustained virologic response (SVR) rate and shortened the treatment duration for patients with chronic hepatitis C virus (HCV) genotype 2 infection. Ribavirin-induced hemolytic anemia is one of the most troublesome side-effects of SOF/RBV therapy; however, factors associated with this condition ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2019, 49(8):853-859]

Cited: 0 times

View full text PDF listing >>



Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.

Akira Doi, Hayato Hikita, Yugo Kai, Yuki Tahata, Yoshinobu Saito, Tasuku Nakabori, Ryoko Yamada, Takahiro Kodama, Ryotaro Sakamori, Asako Murayama, Sayuri Nitta, Yasuhiro Asahina, Hiroshi Suemizu, Tomohide Tatsumi, Takanobu Kato, Tetsuo Takehara,

BACKGROUND:The emergence of a deletion mutant at hepatitis C virus (HCV) NS5A-P32 (P32del) has recently been reported in a subset of chronic hepatitis C patients who experience virologic failure after direct-acting antiviral drug (DAA) treatment. This mutation confers extremely high resistance to NS5A inhibitors. No effective treatment has been established ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2019, 54(5):449-458]

Cited: 2 times

View full text PDF listing >>



Nonstructural protein 5A/P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection.

Akira Doi, Hayato Hikita, Ryotaro Sakamori, Yuki Tahata, Yugo Kai, Ryoko Yamada, Takayuki Yakushijin, Eiji Mita, Kazuyoshi Ohkawa, Yasuharu Imai, Kunimaro Furuta, Takahiro Kodama, Tomohide Tatsumi, Tetsuo Takehara,

Hepatology (Hepatology (Baltimore, Md.))
[2018, 68(1):380-383]

Cited: 7 times

View full text PDF listing >>



Ultra-deep sequencing analysis of resistance-associated variants during retreatment with simeprevir-based triple therapy after failure of telaprevir-based triple therapy in patients with genotype 1 hepatitis C virus infection.

Naoki Morishita, Naoki Hiramatsu, Tsugiko Oze, Ayako Urabe, Yuki Tahata, Ryoko Yamada, Takayuki Yakushijin, Atsushi Hosui, Sadaharu Iio, Akira Yamada, Hideki Hagiwara, Eiji Mita, Yukinori Yamada, Toshifumi Ito, Masami Inada, Kazuhiro Katayama, Iwao Yabuuchi, Yasuharu Imai, Hayato Hikita, Ryotaro Sakamori, Yuichi Yoshida, Tomohide Tatsumi, Norio Hayashi, Tetsuo Takehara,

<h4>Aim</h4>Simeprevir (SMV)-based triple therapy is an effective retreatment option following failure of telaprevir (TVR)-based triple therapy. However, it is unclear whether the persistence of resistance-associated variants (RAVs) induced by TVR-based therapy may reduce the treatment effect of SMV-based therapy.<h4>Methods</h4>The factors associated with the treatment effect, including RAVs in the NS3 ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2017, 47(8):773-782]

Cited: 2 times

View full text PDF listing >>



Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.

Yuki Tahata, Naoki Hiramatsu, Tsugiko Oze, Ayako Urabe, Naoki Morishita, Ryoko Yamada, Takayuki Yakushijin, Atsushi Hosui, Masahide Oshita, Akira Kaneko, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Yukinori Yamada, Masami Inada, Kazuhiro Katayama, Shinji Tamura, Yasuharu Imai, Hayato Hikita, Ryotaro Sakamori, Yuichi Yoshida, Tomohide Tatsumi, Norio Hayashi, Tetsuo Takehara,

The factors associated with sustained virologic response (SVR) in chronic hepatitis C (CH-C) genotype 1 patients treated with simeprevir (SMV), pegylated interferon (Peg-IFN) plus ribavirin (RBV) triple therapy have not been fully investigated. Two hundred and twenty-nine treatment-naïve CH-C patients treated with SMV triple therapy were enrolled in this study. ... Read more >>

J Med Virol (Journal of medical virology)
[2016, 88(10):1776-1784]

Cited: 1 time

View full text PDF listing >>



The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin.

Yuki Tahata, Naoki Hiramatsu, Tsugiko Oze, Naoki Morishita, Naoki Harada, Ryoko Yamada, Takayuki Yakushijin, Eiji Mita, Hideki Hagiwara, Yukinori Yamada, Toshifumi Ito, Taizo Hijioka, Masami Inada, Kazuhiro Katayama, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Keiko Irishio, Michio Kato, Hayato Hikita, Ryotaro Sakamori, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Toshimitsu Hamasaki, Norio Hayashi, Tetsuo Takehara,

<h4>Background</h4>Hyperbilirubinemia, mild or moderate, is a commonly observed laboratory abnormality in chronic hepatitis C patients treated with simeprevir with pegylated interferon (Peg-IFN) plus ribavirin. In this prospective, multicenter study, we aimed to investigate the clinical features and factors associated with bilirubin increases during the therapy.<h4>Methods</h4>A total of 192 patients with ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2016, 51(3):252-259]

Cited: 7 times

View full text PDF listing >>





Advertisement


Disclaimer

2.3489 s